Charles Schwab Investment Management Inc Protalix Bio Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 175,070 shares of PLX stock, worth $374,649. This represents 0.0% of its overall portfolio holdings.
Number of Shares
175,070Holding current value
$374,649% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding PLX
# of Institutions
69Shares Held
8.7MCall Options Held
168KPut Options Held
31.4K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$3.46 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.08MShares$2.31 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA826KShares$1.77 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.496KShares$1.06 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA485KShares$1.04 Million0.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $106M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...